Horizon Pharma gains approval for Ravicti in Europe

1 December 2015

Ireland-incorporated Horizon Pharma (Nasdaq: HZNP) announced yesterday that the European Commission has adopted a binding decision to approve Ravicti (glycerol phenylbutyrate) oral liquid for use as an adjunctive therapy for chronic management of adult and pediatric patients two months of age and older with urea cycle disorders (UCDs).

Ravicti will now cover six subtypes of UCDs, a broader range compared to currently-approved medicines in the EU, and will be easier for patients to use.

Horizon Pharma acquired rights to Ravicti along with its $1.1 billion buy of US firm Hyperion Therapeutics earlier this year (The Pharma Letter March 30). The company recently gave up on its $1.68 billion hostile attempt to acquire Depomed (TPL November 20), aimed at expanding its line of treatments for pain and central nervous system conditions.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK